IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed May 6, 2021 · 10-Q · 36 days after period end · 0001564590-21-025001
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Net Income | -$23.09M | -$17.18M | -$5.68M | -$3.38M |
| EPS Diluted | -$0.78 | -$0.61 | -$1.61 | -$1.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end
